Raemaekers, John M M3; André, Marc P E3; Federico, Massimo3; Girinsky, Theodore3; Oumedaly, Reman3; Brusamolino, Ercole3; Brice, Pauline3; Fermé, Christophe3; van der Maazen, Richard3; Gotti, Manuel3; Bouabdallah, Reda3; Sebban, Catherine J3; Lievens, Yolande3; Re, Allessandro3; Stamatoullas, Aspasia3; Morschhauser, Frank3; Lugtenburg, Pieternella J3; Abruzzese, Elisabetta3; Olivier, Pierre3; Casasnovas, Rene-Olivier3; van Imhoff, Gustaaf3; Raveloarivahy, Tiana3; Bellei, Monica3; van der Borght, Thierry3; Bardet, Stephane3; Versari, Annibale3; Hutchings, Martin1; Meignan, Michel3; Fortpied, Catherine3
1 Onkologisk Klinik, Finsencentret, Rigshospitalet, The Capital Region of Denmark2 Hæmatologisk Klinik, Finsencentret, Rigshospitalet, The Capital Region of Denmark3 unknown
Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial
PURPOSE: Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET) scan could be used to adapt treatment. Therefore, we started the randomized EORTC/LYSA/FIL Intergroup H10 trial evaluating whether involved-node radiotherapy (IN-RT) could be omitted without compromising progression-free survival in patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment. PATIENTS AND METHODS: Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible. Here we report the clinical outcome of the preplanned interim futility analysis scheduled to occur after documentation of 34 events in the early PET-negative group. Because testing for futility in this noninferiority trial corresponds to testing the hypothesis of no difference, a one-sided superiority test was conducted. RESULTS: The analysis included 1,137 patients. In the favorable subgroup, 85.8% had a negative early PET scan (standard arm, one event v experimental arm, nine events). In the unfavorable subgroup, 74.8% had a negative early PET scan (standard arm, seven events v experimental arm, 16 events). The independent data monitoring committee concluded it was unlikely that we would show noninferiority in the final results for the experimental arm and advised stopping random assignment for early PET-negative patients. CONCLUSION: On the basis of this analysis, combined-modality treatment resulted in fewer early progressions in clinical stage I/II HL, although early outcome was excellent in both arms. The final analysis will reveal whether this finding is maintained over time.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2014, Vol 32, Issue 12, p. 1188-94